Clinical Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study Of Mavorixafor In Participants With Congenital And Acquired Primary Autoimmune And Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent And/Or Serious Infections

MOA: Mavorixafor is a CXCR4 antagonist that blocks the binding of the CXCR4 ligand, SDF 1α/CXC chemokine ligand 12.

Key Eligibility:

• Diagnosis of congenital or acquired primary autoimmune and
  idiopathic chronic neutropenic disorder
• Subjects must be receiving G-CSF or other active background
  therapy for the past 12 months with ongoing infections, be on a
  stable dose and schedule for at least 4 weeks before screening,
  and maintain this regimen throughout the study
• Subjects with a diagnosis of secondary neutropenia are excluded
• Subjects with any of the following diagnoses are excluded:
  • Aplastic anemia
  • WHIM syndrome
  • Certain CNs
  • Neutropenia associated with a Duffy-null phenotype